Key result
Angiopoietins are essential in maintaining vascular homeostasis, and therapies targeting the angiopoietin-Tie2 pathway, such as faricimab, show promising efficacy for diabetic retinal diseases.
Why the study?
Diabetic retinopathy is a frequent complication of poorly controlled diabetes whose pathogenesis remains only partially understood.
Angiopoietins play a crucial role in the pathogenesis of diabetic retinopathy, making them a promising therapeutic target.
Answers are grounded in this paper and cite their sources.
May support angiopoietin-targeted therapies in diabetic retinopathy; leaves open confirmation in larger trials.
Diabetic retinopathy is a devastating and frequent complication of poorly controlled diabetes, whose pathogenesis is still only partially understood. Advances in basic research over the last two decades have led to the discovery of angiopoietins, proteins that strongly influence the growth and integrity of blood vessels in many vascular beds, with particular importance in the retina. Angiopoietin 1 (Ang1), produced mostly by pericytes and platelets, and angiopoietin 2 (Ang2), produced mainly by endothelial cells, bind to the same receptor (Tie2), but exert opposing effects on target cells. Ang1 maintains the stability of the mature vasculature, while Ang2 promotes vessel wall destabilization and disruption of the connections between endothelial cells and pericytes. Human retinal endothelial cells exposed to Ang2 show reduced membrane expression of the adhesion molecule VE-cadherin, and patients with proliferative diabetic retinopathy or diabetic macular edema have markedly increased vitreal concentrations of Ang2. Faricimab, a bi-specific antibody simultaneously directed against Ang2 and VEGF, has shown promising results in clinical trials among patients with diabetic retinopathy, and other agents targeting the angiopoietin system are currently in development.
No takes yet. Share an insight, caveat, or question.
Collazos-Alemán et al. (2022) conducted a review in Neovascular Diabetes-Related Retinal Diseases (Diabetic Retinopathy, Diabetic Macular Edema). Angiopoietin-targeted therapies (e.g., Faricimab) was evaluated. Angiopoietins are essential in maintaining vascular homeostasis, and therapies targeting the angiopoietin-Tie2 pathway, such as faricimab, show promising efficacy for diabetic retinal diseases.
Synapse has enriched 10 related papers. Consider them for comparative context: